^
Association details:
| Biomarker: | TMB-L + LDH elevation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + Cotellic (cobimetinib) (MEK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation–positive advanced melanoma.
Published date:
05/19/2021
Excerpt:
The RPA analysis included 208/256 (81.3%) patients (pts) from the A+V+C arm of IMspire150...Pts with e-LDH and TMB < 10 mut/Mb had poor PFS outcomes, with 2-y PFS rates of 9% and 3% and lower rates of OR (51% and 62%) and CR (5% and 9%) in the A+V+C and P+V+C arms, respectively.
DOI:
10.1200/JCO.2021.39.15_suppl.9523
